Submission of Earnings Call Transcript for Q4 FY26.

Sudeep Pharma reported FY26 revenue of INR642.3 crores (up 28% YoY) and PAT of INR174.3 crores. EBITDA margin declined to 34.6% from 37.8% due to raw material inflation, one-time expenses including INR3 crores CSR, air freight costs, and LPG premiums, plus upfront investments in building Europe and North America teams. Specialty ingredients emerged as the fastest-growing segment with 62% revenue growth to INR280 crores, now contributing 44% of total revenues. The company has 42 customers in pipeline for battery materials with 700 MT of initial commercial orders received. The new greenfield facility has completed internal validation and is in customer approval stage (6-12 months). Management guided that pharma food and nutrition should grow faster than FY26's 10%, specialty ingredients will maintain momentum, and margins should track back to 37-38% historical levels as one-time costs normalize.